ZYBERNO
Stock Report
Updated Sep 1, 2026

CEL-SCI CORPORATION (CVM)

Healthcare • NYSE

$1.62

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
2.0/100
POOR BUSINESS
CEL-SCI CORPORATION (CVM) scores 2/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-202.1%)
Debt-to-Equity (Solvency Risk):POOR (1.29x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-82.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

CEL-SCI CORPORATION (CVM) stock report — Zyberno Score 2/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, CVM generated -$17.01M in Owner Earnings. Capital was deployed as follows: $5.16K invested in capital expenditures. Reinvestment rate: 12.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.62
Market Cap:$28.49M

Valuation Multiples (2)

P/B Ratio:2.60x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$37.69M

Price Action & Momentum (1)

% of 52-Week High:12.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-100.8%
Reinvestment Rate:12.1%
Fundamental Growth Rate (g):-10.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$424.68
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:67.5%
Latest Earnings Filed:2026-08-14
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.48x
Quick Ratio:1.02x
Cash Ratio:0.00x

Leverage Analysis (3)

Debt To Equity Ttm:1.29x
Debt-to-Equity Ratio:1.29x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-132.32x
Times Interest Earned:-132.32

Capital Structure (4)

Working Capital:2,424,296.00
Cash And Cash Equivalents:0.00
Long Term Debt:$6.27M
Net Debt:$9.20M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$22.29M

Bottom Line Performance (3)

-$22.70M
Income Before Tax:$0.00
Ebitda Ttm:-20,350,160.00

Operating Expenses (5)

Operating Expenses:22,285,432.00
R And D Expense:14,796,786.00
Sga Expense:7,488,646.00
Income Tax Expense:$0.00
Interest Expense:187,495.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$21.36M
Current Assets:$7.50M
Ppe Net:4,578,795.00
Goodwill:0.00
Intangible Assets:$69.69K

Liability Structure (4)

Total Liabilities:10,399,628.00
Current Liabilities:5,079,671.00
Long Term Debt:$6.27M
Short Term Debt:$2.93M

Equity & Capital (3)

Equity:$10.96M
Retained Earnings:-$556.03M
Common Stock:600,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:2,347,049.00
Accounts Payable:1,023,200.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:443,275.00
C. Cash Flow Analysis

Operating Activities (2)

-$17.00M-$17.01M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:5,155.00

Financing Activities (3)

Financing Cash Flow:-$653.77K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$350.00K
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:1,935,272.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (2)

-$6.54
Earnings Per Share Ttm:-$1.29

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.97

Book Value & Capital (2)

Book Value Per Share:$0.62
Cash Per Share:-999.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$17.01M

Damodaran Growth Analysis (2)

Reinvestment Rate:12.1%
Fundamental Growth Rate (g):-10.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-29.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:CVM
Company Name:CEL-SCI CORPORATION
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:17.59M
Shares Outstanding Basic:17.59M
Shares Outstanding Diluted:12.12M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 12:56:00 UTC
Data Timestamp:2026-08-21T06:35:15.230681
Scroll to Top